Search results
IBS: Artificial sweetener neotame may damage gut bacteria
Medical News Today· 1 hour agoNeotame is a sweetener formulated to be an ingredient in baked goods, various other food products, and as a tabletop flavoring. The study will result in fresh risk/benefit considerations of ...
Antidepressants Differ by Long-Term Response in Major Depression
Psychiatric Times· 7 days agoAntidepressants differ in improving symptoms and preventing relapse of major depressive disorder...
... Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment...
NewMediaWire via Yahoo Finance· 4 days agoLIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with...
Novel Agent Curbs Alzheimer's-Related Agitation
Medscape· 6 days agoMore than half of participants in the open-label extension period of the randomized clinical trial responded to the medication, which was associated with...
New Trials in Prostate Cancer: Could Your Patient Benefit?
Medscape· 11 hours agoPerhaps one of your patients could benefit from a clinical trial that has recently opened in...
Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits
FOX21 Colorado Springs· 5 hours agoNanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Samarendra Mohanty, PhD, Co-Founder ...
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
WWTI Watertown· 4 days agoThe company anticipates topline results from both trials in the second half of 2024...planned New...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 5 hours ago(the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that the company has reached target enrollment ...
MannKind advances new inhaled NTM lung disease treatment By Investing.com
Investing.com· 5 hours agoThe ICoN-1 trial will be a multi-national, randomized, double-blind, placebo-controlled study...
PhaseV and Quanticate partner to help sponsors run more adaptive trials
Clinical Trials Arena via Yahoo Finance· 3 days agoHowever, for that to happen, sponsors need to overcome some major challenges including operational...
